SANTEN PHARMACEUTICAL CO., LTD.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Public

Established: 1890-01-01

Employees: 3.7K

Market Cap: $4.5B

Website: http://www.santen.co.jp

Clinical Trials

A Study in Chinese Patients With Acquired Blepharoptosis

Phase 3

Recruiting

Conditions: Blepharoptosis

Interventions: Drug: STN1013800 ophthalmic solution
Drug: STN1013800 ophthalmic solution Liquid Base, without STN1013800

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 180

Registration Number: NCT06683651

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China

and more 18 locations

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Phase 3

Not yet recruiting

Conditions: Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: DE-117B Eye Drops
Drug: Latanoprost

First Posted Date: 2024-10-31

Last Posted Date: 2024-11-04

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 338

Registration Number: NCT06666855

Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Phase 1

Completed

Conditions: Healthy Adult Males Volunteers

Interventions: Drug: STN1012600 ophthalmic solution 0.002%

First Posted Date: 2023-06-15

Last Posted Date: 2023-12-05

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 8

Registration Number: NCT05905653

Locations: 🇯🇵
Medical Corporation Heishinkai OPHAC Hospital, Osaka, Japan

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open Angle Glaucoma, Ocular Hypertension

Interventions: Drug: STN1012600 ophthalmic solution 0.002%
Drug: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%

First Posted Date: 2022-08-17

Last Posted Date: 2024-07-15

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 131

Registration Number: NCT05503901

Locations: 🇯🇵
Kitanagoya Eye Clinic, Aichi, Japan
🇯🇵
Miyake Eye Hospital, Aichi, Japan
🇯🇵
Nagasaka Eye Clinic, Aichi, Japan

and more 15 locations

A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension

Interventions: Drug: STN1012600 ophthalmic solution 0.002%
Drug: Latanoprost ophthalmic solution 0.005%

First Posted Date: 2022-08-10

Last Posted Date: 2023-12-05

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 325

Registration Number: NCT05495061

Locations: 🇯🇵
Maeda Eye Clinic, Osaka, Japan
🇯🇵
IMAI Eye Clinic, Yamanashi, Japan
🇯🇵
Mitsuhashi Eye Clinic, Chiba, Japan

and more 41 locations

A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Open-angle Glaucoma, Ocular Hypertension

Interventions: Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL
Drug: A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL

First Posted Date: 2019-01-30

Last Posted Date: 2023-07-14

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 219

Registration Number: NCT03822559

Locations: 🇨🇳
Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital, Changsha, China
🇨🇳
Eye & Ent Hospital of Fudan University, Shanghai, China

A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)

Phase 2

Completed

Conditions: Myopia

Interventions: Drug: DE-127 Ophthalmic Solution low dose
Drug: Placebo Ophthalmic Solution
Drug: DE-127 Ophthalmic Solution medium dose
Drug: DE-127 Ophthalmic Solution high dose

First Posted Date: 2017-11-06

Last Posted Date: 2020-08-26

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 99

Registration Number: NCT03329638

Locations: 🇸🇬
Singapore National Eye Centre, Singapore, Singapore

Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease

Phase 1

Completed

Conditions: Dry Eye Disease

Interventions: Drug: Placebo ophthalmic solution and 3% DE-089 ophthalmic solution

First Posted Date: 2017-07-13

Last Posted Date: 2018-08-31

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 20

Registration Number: NCT03216096

Locations: 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇨🇳
Keelung Chang Gung Memorial Hospital, Keelung, Taiwan

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

Phase 3

Completed

Conditions: Open Angle Glaucoma or Ocular Hypertension

Interventions: Drug: DE-117
Drug: Latanoprost ophthalmic solution

First Posted Date: 2016-12-05

Last Posted Date: 2024-03-15

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 370

Registration Number: NCT02981446

A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery

Phase 3

Completed

Conditions: Cataract

Interventions: Device: MD-15 Intraocular Lens

First Posted Date: 2016-09-02

Last Posted Date: 2018-02-27

Lead Sponsor: Santen Pharmaceutical Co., Ltd.

Target Recruit Count: 110

Registration Number: NCT02888210

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy